



Cornerstone Pharmaceuticals, Inc.
1 Duncan Drive
Cranbury, NJ 08512

Media Contact: David Polinsky
Cornerstone Pharmaceuticals, Inc.
(609) 409 -7050 ext 202
news@cornerstonepharma.com

CORNERSTONE PHARMACEUTICALS ANNOUNCES SPEAKING ENGAGEMENT OF DR. PAUL BINGHAM AT BioX 2012 CONFERENCE

CRANBURY, NJ (September 24, 2012) Cornerstone Pharmaceuticals, Inc. (www.cornerstonepharma.com), a leader in the growing field of cancer metabolism-based therapeutics, is pleased to announce the invitation of Paul Bingham, Ph.D., Vice President of Research, to present on Monday, September 24, 2012 at BioX 2012 at the University of Connecticut, Stamford Campus. Dr. Bingham will be part of the 1:00-2:05 PM panel presentation entitled "Targeted Oncology - Changing the Course of Cancer Therapy, Again" about cancer metabolism and targeting altered energy production, to be held at the Main Meeting Hall.

BioX 2012 is Noble Financial Capital Markets' Life Sciences Exposition. Following the event, a high-definition video webcast of Cornerstone's presentation and a copy of the presentation materials will be available on Noble Financial websites: <http://www.noblefcm.com> or <http://www.nobleresearch.com/BioExposition.htm>. A Microsoft SilverLight viewer (a free download from the presentation link) is required to participate. The webcast will be archived for 90 days following the event.

Dr. Robert Shorr, Chief Executive Officer of Cornerstone, commented "We are pleased that Dr. Bingham was invited to share his expertise at the BioX 2012 conference. This is another exciting opportunity for Cornerstone Pharmaceuticals to contribute to the dialogue about tumor metabolism with respected industry and academic leaders, and we thank Dr. Bingham for agreeing to participate in this cutting-edge conference."

CPI-613, the lead drug candidate from Cornerstone's proprietary AEMD platform, disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential "bioenergetic" differences are linked to pathways that control, among other things, cancer cell growth and development, as well as various forms of cell death, including apoptosis and necrosis. The platform is designed to produce drugs, such as CPI-613, that disrupt energy-production pathways whose organization or regulation are altered specifically in cancer cells. CPI- 613 is currently being evaluated in multiple clinical trials.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management, and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research, and drug development. The company's unique approach to targeting cancer metabolism has



led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated.

###

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.